Product Information
GLUMETZA ER 500 MG TABLET is a brand product labeled by Santarus Inc., priced at $49.2115 per EA under NDC 68012000450. Its NADAC has been published 222 times since Aug 8, 2018.
FDA first approved this application on Jun 3, 2005.
The High Outlier badge above means this manufacturer's average price in the metformin hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
500 mg/1
Manufacturer
Santarus Inc.NDC
68012000450
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
1/22/2025
Active Ingredients
METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA021748FDA Approved
6/3/2005
On Market Since
3/20/2018
Pharmacological Classes
Price Statistics
The NADAC for GLUMETZA ER 500 MG TABLET has been published 222 times since Aug 8, 2018, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.2115 per EA |
|---|---|
| All-time high | $49.5423 (Apr 10, 2024) |
| All-time low | $49.2115 (Jan 22, 2025) |
| Median price | $49.4465 |
| Average price | $49.4176 |
| Largest weekly change | -0.4% (Apr 17, 2024) |
| Weeks tracked | 222 |
| Tracking since | Aug 8, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-0.7%
5Y
-0.5%
All
-0.5%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Santarus Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLUMETZA ER 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLUMETZA ER 500 MG TABLET, manufactured by Santarus Inc., is $49.2115 per EA (NDC 68012000450), effective Oct 1, 2025.
How has the price of GLUMETZA ER 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLUMETZA ER 500 MG TABLET has held within roughly two percent of its current level. It has been tracked across 222 weekly CMS publications since Aug 8, 2018.
What are the highest and lowest recorded NADAC prices for GLUMETZA ER 500 MG TABLET?
Since Aug 8, 2018, the NADAC for GLUMETZA ER 500 MG TABLET has ranged from a low of $49.2115 (Jan 22, 2025) to a high of $49.5423 (Apr 10, 2024), with a median of $49.4465 per EA.
Are there cheaper alternatives to GLUMETZA ER 500 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METFORMIN HCL 500 MG TABLET, is $0.0145 per EA — about 99% below GLUMETZA ER 500 MG TABLET.
Who manufactures GLUMETZA ER 500 MG TABLET?
GLUMETZA ER 500 MG TABLET (NDC 68012000450) is labeled by Santarus Inc., and CMS classifies it as a brand product.